These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38211606)

  • 21. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
    Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
    Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Liu LT; Liu H; Huang Y; Yang JH; Xie SY; Li YY; Guo SS; Qi B; Li XY; Chen DP; Jin F; Sun XS; Yang ZC; Liu SL; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Qiu F; Yang Q; Liang YJ; Jia GD; Wen DX; Yan JJ; Zhao C; Chen QY; Sun R; Tang LQ; Mai HQ
    Lancet Oncol; 2023 Jul; 24(7):798-810. PubMed ID: 37290468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
    Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial.
    Liu X; Zhang X; Jiang S; Mo M; Wang Q; Wang Y; Zhou L; Hu S; Yang H; Hou Y; Chen Y; Lu X; Wang Y; Zhou X; Li W; Chang C; Yang X; Chen K; Cao J; Xu Q; Sun Y; Luo J; Luo Z; Hu X
    Lancet Oncol; 2024 Aug; 25(8):1092-1102. PubMed ID: 39068945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
    Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
    Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
    Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
    Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
    Saji S; Taira N; Kitada M; Takano T; Takada M; Ohtake T; Toyama T; Kikawa Y; Hasegawa Y; Fujisawa T; Kashiwaba M; Ishida T; Nakamura R; Yamamoto Y; Toh U; Iwata H; Masuda N; Morita S; Ohno S; Toi M
    Lancet Oncol; 2022 May; 23(5):636-649. PubMed ID: 35405087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.